Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 3Ganglioneuroblastoma 3Vaginal Neoplasms 2Neuroblastoma 2Wilms Tumor 1Thoracic Diseases 1Testicular Neoplasms 1Teratoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Germ Cell Cancer 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Endodermal Sinus Tumor 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioma × Congresses as Topic × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡